Prostate Health Market Detail Analysis of Current and Future Projection 2023 to 2033Posted by Ganesh Shinde on February 8th, 2023  The global Prostate Health Market is expected to reach US$ 92.9 billion in 2033, up from US$ 38.6 billion in 2023, at a 9.2% CAGR between 2023 and 2033. While BPH (Benign Prostate Hyperplasia) rarely develops symptoms before the age of 40, the risk of the disease grows with age. Approximately half of guys between the ages of 51 and 60 are impacted, while up to 90% of men over the age of 80 are affected. Patients with BPH have been treated with medications and surgery. Grants for BPH treatment research and the fact that obesity causes several mechanisms, including increased sympathetic nervous activity, increased inflammation process, and oxidative stress, all of which are conducive to the development of BPH, are likely to accelerate prostate health market growth. Cancer patients are at higher risk of COVID-19 infection than adults with good prostate health, according to major regulatory bodies around the world (such as the WHO, MHRA, TGA, and EMA) and screening, diagnostic exams, and surgical procedures in hospitals and cancer centres are severely limited or postponed. As a result, caregivers and hospitals can expect delays in elective surgeries and screening procedures. However, since the second half of 2020, the market has gradually increased due to an increase in the number of oncology appointments and rise in adoption of prostate health therapies, among other things, as a result of efforts to clear backlogs and new cases, which further shapes the prostate health market future trends. Competitive Landscape: AstraZeneca plc, Bristol-Myers Squibb Company, Astellas Pharma Inc., F. Hoffmann-La Roche AG, Bayer AG, erring Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Ipsen Pharma, Johnson & Johnson, Takeda Pharmaceutical Company Ltd. and GlaxoSmithKline Plc are among the key players in the prostate health market. Read More@ https://www.futuremarketinsights.com/reports/prostate-health-market Key Segments By Disease Indication:
Like it? Share it! More by this author |